Figure 4.

SIRT2/cMYC has antioxidant effects on CCA by promoting the downstream SSP pathway.

(A) HuCCT1 and RBE cells were treated with 0, 25, or 50 μM Tm and the levels of ROS were detected. (B) CCA cells were treated with NAC, Tm, or a combination of both. The levels of T-GSH, GSSG, and GSH were detected. (C & D) CCA cells were treated with or without indicated Tm. The levels of pyruvate and serine were detected by MS. The relative mRNA levels of PHGDH, PSAT1, and PSPH were detected by qPCR. (E) The expressions of PHGDH, PSAT1, and PSPH in the HIBEpic and CCA cells were determined by western blotting. (F) CCA cells were treated with 0, 25, or 50 μM Tm and the levels of PHGDH, PSAT1, and PSPH were detected by Western blotting. (G) CCA cells were transfected with siRNA of cMYC and subjected to western blotting. Data represent mean ± SEM, n ≥ 3. *P < .05 and **P < .01